Satt Paris-Saclay portfolio company EG 427 has collected $14m in its first funding round.

EG 427, a France-based gene therapy developer, raised €12m ($14m) in its series A round led by private investor David Lamond today.
A range of unnamed family offices from San Francisco also participated in the round.
EG 427 is working on pinpoint gene therapy that exploits the Herpes simplex virus 1 to treat patients suffering from severe, chronic and localised diseases. It is is initially focused on peripheral nervous system disorders.
The spinout was founded by regional…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in